About Altimmune, Inc.
https://altimmune.comAltimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis.
CEO
Vipin K. Garg
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2018-09-14 | Reverse | 1:30 |
| 2017-05-05 | Forward | 10:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 88
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
B. Riley Securities
Buy
UBS
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:6.37M
Value:$26.64M
BLACKROCK, INC.
Shares:6.37M
Value:$26.64M
BLACKROCK INC.
Shares:5.32M
Value:$22.24M
Summary
Showing Top 3 of 184
About Altimmune, Inc.
https://altimmune.comAltimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $5K | $5.9M ▼ | $-19.01M ▲ | -380.28K% ▲ | $-0.21 ▲ | $-18.49M ▲ |
| Q2-2025 | $5K | $22.93M ▲ | $-22.15M ▼ | -442.92K% ▼ | $-0.27 ▼ | $-21.85M ▼ |
| Q1-2025 | $5K | $21.82M ▼ | $-19.57M ▲ | -391.5K% ▲ | $-0.26 ▲ | $-20.23M ▲ |
| Q4-2024 | $5K | $24.87M ▲ | $-23.18M ▼ | -463.6K% ▼ | $-0.33 ▼ | $-23.15M ▼ |
| Q3-2024 | $5K | $24.77M | $-22.84M | -456.9K% | $-0.32 | $-22.8M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $210.78M ▲ | $218.45M ▲ | $32.85M ▲ | $185.6M ▲ |
| Q2-2025 | $183.1M ▲ | $190.35M ▲ | $28.98M ▲ | $161.37M ▲ |
| Q1-2025 | $149.83M ▲ | $157.26M ▲ | $15.1M ▼ | $142.16M ▲ |
| Q4-2024 | $131.89M ▼ | $139.31M ▼ | $15.8M ▲ | $123.51M ▼ |
| Q3-2024 | $139.38M | $147.86M | $14.49M | $133.38M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-19.01M ▲ | $-11.9M ▲ | $-149.32M ▼ | $39.35M ▼ | $-121.87M ▼ | $-11.9M ▲ |
| Q2-2025 | $-22.15M ▼ | $-19.65M ▼ | $101.11M ▲ | $52.54M ▲ | $134M ▲ | $-19.66M ▼ |
| Q1-2025 | $-19.57M ▲ | $-16.84M ▲ | $-5.1M ▼ | $34.12M ▲ | $12.18M ▲ | $-16.84M ▲ |
| Q4-2024 | $-23.18M ▼ | $-18.27M ▲ | $13.63M ▲ | $10.09M ▲ | $5.45M ▲ | $-18.27M ▲ |
| Q3-2024 | $-22.84M | $-27.12M | $1.2M | $266K | $-25.65M | $-27.12M |
Revenue by Products
| Product | Q1-2021 | Q2-2021 | Q3-2021 | Q4-2021 |
|---|---|---|---|---|
 Grant | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Vipin K. Garg
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2018-09-14 | Reverse | 1:30 |
| 2017-05-05 | Forward | 10:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 88
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
B. Riley Securities
Buy
UBS
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:6.37M
Value:$26.64M
BLACKROCK, INC.
Shares:6.37M
Value:$26.64M
BLACKROCK INC.
Shares:5.32M
Value:$22.24M
Summary
Showing Top 3 of 184